Corteva (NYSE:CTVA) Lowered to Neutral Rating by JPMorgan Chase & Co.

JPMorgan Chase & Co. cut shares of Corteva (NYSE:CTVA) from an overweight rating to a neutral rating in a research report sent to investors on Thursday morning, Marketbeat Ratings reports. JPMorgan Chase & Co. currently has $77.00 price objective on the stock, up from their previous price objective of $75.00.

A number of other equities analysts have also recently issued reports on CTVA. Rothschild & Co Redburn decreased their target price on Corteva from $71.00 to $65.00 and set a “neutral” rating on the stock in a report on Tuesday, November 11th. Argus upgraded Corteva to a “strong-buy” rating in a report on Friday, January 16th. The Goldman Sachs Group upped their price objective on shares of Corteva from $77.00 to $78.00 and gave the company a “buy” rating in a research note on Tuesday, December 16th. Wall Street Zen raised shares of Corteva from a “hold” rating to a “buy” rating in a research report on Saturday, January 17th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Corteva in a research report on Monday, December 29th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $81.84.

Corteva Price Performance

Shares of Corteva stock opened at $72.50 on Thursday. Corteva has a 52 week low of $53.40 and a 52 week high of $77.41. The company has a current ratio of 1.43, a quick ratio of 1.07 and a debt-to-equity ratio of 0.07. The stock has a market cap of $48.99 billion, a PE ratio of 45.89, a price-to-earnings-growth ratio of 1.86 and a beta of 0.75. The company’s 50-day moving average price is $68.72 and its two-hundred day moving average price is $68.43.

Corteva (NYSE:CTVA) last announced its quarterly earnings data on Tuesday, February 3rd. The company reported $0.22 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.22. Corteva had a net margin of 6.29% and a return on equity of 9.06%. The company had revenue of $3.91 billion for the quarter, compared to analysts’ expectations of $4.23 billion. During the same quarter in the previous year, the company posted $0.32 EPS. The business’s revenue was down 1.7% compared to the same quarter last year. Corteva has set its FY 2026 guidance at 3.450-3.700 EPS. As a group, sell-side analysts anticipate that Corteva will post 2.96 EPS for the current fiscal year.

Corteva Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 16th. Investors of record on Monday, March 2nd will be given a dividend of $0.18 per share. The ex-dividend date of this dividend is Monday, March 2nd. This represents a $0.72 dividend on an annualized basis and a yield of 1.0%. Corteva’s payout ratio is presently 45.57%.

Hedge Funds Weigh In On Corteva

Institutional investors and hedge funds have recently modified their holdings of the stock. Gladwyn Financial Advisors Inc. purchased a new position in Corteva in the second quarter valued at about $25,000. Activest Wealth Management lifted its holdings in shares of Corteva by 118.3% during the 3rd quarter. Activest Wealth Management now owns 369 shares of the company’s stock valued at $25,000 after buying an additional 200 shares during the last quarter. JPL Wealth Management LLC bought a new stake in shares of Corteva in the 3rd quarter valued at approximately $25,000. True Wealth Design LLC increased its holdings in Corteva by 209.5% in the third quarter. True Wealth Design LLC now owns 390 shares of the company’s stock worth $26,000 after buying an additional 264 shares during the last quarter. Finally, Total Investment Management Inc. bought a new position in Corteva during the second quarter valued at approximately $27,000. 81.54% of the stock is currently owned by hedge funds and other institutional investors.

More Corteva News

Here are the key news stories impacting Corteva this week:

• Positive Sentiment: RBC raised its price target to $89 and kept an “outperform” rating, signaling sizable upside from current levels and supporting bullish investor views. RBC raises price target
• Positive Sentiment: Management raised FY‑2026 EPS guidance to $3.45–$3.70 (above Street consensus ~3.23) and the company highlighted record free cash flow and a strong second half, which underpin longer‑term earnings visibility. Guidance and metrics Earnings highlights
• Neutral Sentiment: Analyst views are mixed across the sector, with some firms more cautious and others bullish — adding to day‑to‑day volatility as investors weigh differing valuations and demand outlooks. Conflicting analyst sentiments
• Neutral Sentiment: Full earnings materials and the call transcript are available; they show operational detail that investors will parse (product mix, regional timing) — useful for medium‑term positioning but containing both upside and downside signals. Earnings transcript
• Negative Sentiment: JPMorgan downgraded CTVA from “overweight” to “neutral,” citing limited valuation upside despite raising its target slightly to $77 — a headline catalyst for selling pressure. JPMorgan downgrade
• Negative Sentiment: Corteva missed Q4 revenue expectations as seasonal timing shifts and weaker crop protection/seed demand weighed, and the company reported a wider loss after hours — immediate negative for near‑term sentiment and the main driver of the intraday drop. Revenue miss article After-hours reaction

Corteva Company Profile

Corteva, Inc (NYSE: CTVA) is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva’s operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.